Business Context and Reporting Period
Company: Biorestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 21, 2026
Reporting Period: The filing addresses a delinquency regarding the Quarterly Report on Form 10-Q for the period ended June 30, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes and Compliance Status
- Delinquency Notification: The Company received a notice from Nasdaq on August 21, 2026, citing failure to timely file the Form 10-Q for the quarter ended June 30, 2026.
- Rule Violation: The Company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1), which mandates the timely filing of periodic financial reports.
- Current Listing Status: The common stock continues to trade on the Nasdaq Capital Market under the symbol "BRTX" with no immediate effect on listing status.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has until October 20, 2026, to submit a plan to regain compliance.
- Potential Extension: If Nasdaq accepts the compliance plan, the Company may receive an exception of up to 180 calendar days, extending the deadline to February 16, 2027.
- Appeal Rights: If the compliance plan is rejected, the Company retains the right to appeal to a Nasdaq Hearings Panel.
- Management Action: Management states it is working prudently to complete and file the Form 10-Q and submit the required compliance plan.
- Key Risks: Risks include the inability to complete financial statements in a timely manner, rejection of the compliance plan by Nasdaq, and potential delisting if compliance is not regained within the prescribed period.
Investor Verification Checklist
- Verify the submission date and acceptance status of the Company's compliance plan by October 20, 2026.
- Monitor the filing status of the Form 10-Q for the quarter ended June 30, 2026.
- Review any subsequent communications from Nasdaq regarding the extension period or potential delisting proceedings.
- Assess the Company's ability to maintain internal resources necessary for timely financial reporting.